Introduction SARS-CoV-2 vaccination is an effective means to prevent severe illness and death due to SARS-CoV-2 infection[1].Vaccine safety has been carefully monitored to be sure that the benefit outweighs the risk o...Introduction SARS-CoV-2 vaccination is an effective means to prevent severe illness and death due to SARS-CoV-2 infection[1].Vaccine safety has been carefully monitored to be sure that the benefit outweighs the risk of adverse events(AEs).Common AEs of the BNT162b2 mRNA vaccine,for example,include fatigue(45%),headache(40%),and chills(28%)after the first administration in accordance with the adult phase Ⅲ clinical trial[1].展开更多
基金supported in part by a grant of the collaborative studies for radiation disasters and medical science in the Fukushima Medical University(Fukushima,Japan)the internal fund of the Soma Central Hospital(Soma,Fukushima,Japan)the Medical Governance Research Institute(Minato-ward,Tokyo,Japan).
文摘Introduction SARS-CoV-2 vaccination is an effective means to prevent severe illness and death due to SARS-CoV-2 infection[1].Vaccine safety has been carefully monitored to be sure that the benefit outweighs the risk of adverse events(AEs).Common AEs of the BNT162b2 mRNA vaccine,for example,include fatigue(45%),headache(40%),and chills(28%)after the first administration in accordance with the adult phase Ⅲ clinical trial[1].